8-K: Compass Therapeutics Q1 2026 Results: Tovecimig Data Promising

Compass Therapeutics reported Q1 2026 financial results, highlighting positive Phase 2/3 data for tovecimig in biliary tract cancer and updates on other pipeline candidates.

Summary

• Compass Therapeutics announced its first quarter 2026 financial results and provided a corporate update.
• The company reported positive Phase 2/3 study data for tovecimig in biliary tract cancer (BTC), showing statistically significant improvement in progression-free survival (PFS) and a clear signal of survival benefit.
• Tovecimig received Orphan Drug Designation in April 2026 and Compass plans to meet with the FDA for a Biologics License Application (BLA) submission later this year.
• The Phase 1 study of CTX-8371 (PD-1 x PD-L1 bispecific antibody) has been selected for a poster presentation at ASCO 2026, with cohort expansions initiated in TNBC, NSCLC, and HL.
• The Phase 1 study for CTX-10726 (PD-1 x VEGF-A bispecific antibody) has been initiated, with initial data expected in Q4 2026.
• The company ended Q1 2026 with $195 million in cash and marketable securities, which is expected to fund operations into 2028.
• Net loss for Q1 2026 was $18.3 million, or $0.10 per common share, compared to $16.6 million, or $0.12 per common share, in Q1 2025.
• R&D expenses increased slightly to $13.4 million in Q1 2026 from $13.1 million in Q1 2025, while G&A expenses increased to $6.9 million from $4.9 million, driven by pre-commercialization and stock compensation costs.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report due to strong clinical data for tovecimig and a solid cash position, though increased G&A expenses are a minor concern.

Positives

• Tovecimig Phase 2/3 study demonstrated a highly statistically significant improvement in progression-free survival (PFS) (4.7 months vs. 2.6 months, HR=0.44, p<0.0001) and clear signals of survival benefit in biliary tract cancer patients.
• Tovecimig achieved an Overall Response Rate (ORR) of 17.1% in the combination arm versus 5.3% for paclitaxel alone (p=0.031).
• Tovecimig received Orphan Drug Designation in April 2026.
• The company has sufficient cash and marketable securities ($195 million as of March 31, 2026) to fund operations into 2028.
• CTX-8371 Phase 1 study showed deep responses in TNBC, NSCLC, and HL patients in the post-checkpoint inhibitor setting.
• The net loss per share improved to $0.10 in Q1 2026 from $0.12 in Q1 2025.

Negatives

• General and Administrative (G&A) expenses increased by 41% to $6.9 million in Q1 2026 compared to Q1 2025, primarily due to pre-commercialization expenses and higher stock compensation.
• Cash and marketable securities decreased by $14 million from December 31, 2025, to March 31, 2026.
• The overall survival data for tovecimig was confounded by high crossover from the control arm, making direct comparison difficult.

Risks

• The company's ability to raise additional funding needed to pursue its business and product development plans.
• The inherent uncertainties associated with developing product candidates and operating as a development stage company.
• Compass's ability to identify additional product candidates for development.
• Compass's ability to develop, complete clinical trials for, obtain approvals for, and commercialize any of its product candidates.
• Competition in the industry in which Compass operates.
• Market conditions.
• The potential for new safety signals to emerge in ongoing or future clinical trials.
• Regulatory approval timelines and potential challenges in the BLA submission process for tovecimig.

Future Outlook

Compass Therapeutics expects its current cash and marketable securities of $195 million to fund operations into 2028. The company plans to submit a Biologics License Application (BLA) for tovecimig later this year and expects initial data from CTX-10726 in Q4 2026, with additional data from CTX-8371 cohort expansions also expected in Q4 2026. A Phase 2 trial for CTX-471 is anticipated to initiate in the second half of 2026.

Management Comments

• "Most patients with BTC have no approved therapeutic option in the second line setting. Tovecimig, with its strong response rate, striking progression benefit and impact on overall survival would be a compelling treatment alternative for these patients," said Thomas Schuetz, MD, PhD, Chief Executive Officer and Vice Chairman of the Board of Directors.
• "In the post-checkpoint inhibitor setting where treatment alternatives are also critically needed, we have ongoing studies with very two promising candidates."
• "Our novel PD-1 x PD-L1 checkpoint inhibitor CTX-8371 continues to demonstrate strong and durable clinical activity and we look forward to presenting dose-escalation and early expansion cohort data at ASCO."
• "CTX-10726, our differentiated PD-1 x VEGF-A bispecific antibody, is also in a Phase 1 study and we expect to share initial data later this year."

Industry Context

StockSavvy.ai notes that Compass Therapeutics' focus on bispecific antibodies targeting multiple pathways in oncology aligns with a broader industry trend towards more targeted and combination therapies. The positive data for tovecimig in biliary tract cancer, a difficult-to-treat indication, is significant, especially given the unmet need in the second-line setting. The progress in the CTX-8371 and CTX-10726 programs also reflects the ongoing development of novel immuno-oncology agents.

Comparison to Industry Standards

• The ORR of 17.1% for tovecimig in combination with paclitaxel for second-line BTC is competitive, considering the historical ORR for single-agent chemotherapy in this setting is typically in the low single digits.
• The PFS of 4.7 months for the tovecimig combination is a notable improvement over paclitaxel alone (2.6 months) and compares favorably to other treatments in the second-line BTC setting, where median PFS can range from 2-4 months.
• The OS data, while confounded by crossover, showed a median of 9.8 months for all patients treated with tovecimig, which is an improvement over historical benchmarks for second-line BTC, often around 6-8 months.
• The development of PD-1 x PD-L1 and PD-1 x VEGF-A bispecific antibodies like CTX-8371 and CTX-10726 is in line with industry efforts to overcome resistance to existing checkpoint inhibitors and target tumor microenvironment components.

Stakeholder Impact

• Shareholders: Positive impact from promising clinical data for tovecimig and a long cash runway, potentially increasing future value.
• Patients: Potential benefit from tovecimig as a new treatment option for biliary tract cancer, addressing an unmet medical need.
• Employees: Continued investment in R&D and potential pre-commercialization activities may indicate growth and future opportunities.
• Creditors: The company's substantial cash reserves provide a degree of financial stability.

Next Steps

• Meet with the FDA in advance of the planned BLA submission for tovecimig later this year.
• Present Phase 1 dose-escalation and early expansion cohort data for CTX-8371 at ASCO 2026.
• Initiate cohort expansions for CTX-8371 in TNBC, NSCLC, and HL.
• Share initial data from the Phase 1 study of CTX-10726 in Q4 2026.
• Share additional data from CTX-8371 cohort expansions in Q4 2026.
• Initiate Phase 2 trial of CTX-471 in the second half of 2026.
• Continue ongoing investigator-sponsored trial of tovecimig in combination with gemcitabine, cisplatin, and durvalumab.

Key Dates

Recommendation

The company presented encouraging clinical data for tovecimig and has a strong cash position, supporting a 'hold' recommendation. However, the path to commercialization involves significant regulatory hurdles and further clinical development, alongside competition. The increase in G&A expenses warrants monitoring. A 'strong buy' would require more definitive regulatory pathways or earlier-stage pipeline breakthroughs.

Keywords

Compass Therapeutics, Tovecimig, CTX-8371, CTX-10726, Oncology, Biliary Tract Cancer, Biopharmaceutical, Clinical Trials